REPL News and Press, Replimune Group Inc. From 07/23/25

New York, New York--(Newsfile Corp. - July 23, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal securities laws. If you invested in Replimune, you are encouraged to...

2025-07-23 13:11:55 ET DENVER, Colo., Jul 23, 2025 ( 247marketnews.com )- The recent meme-stock frenzy features Kohl’s (NYSE: KSS) , GoPro (NASDAQ:GPRO) , Krispy Kreme (NASDAQ:DNUT) , Koss (NASDAQ:KOSS) , Beyond Meat (NASDAQ:BYND) , and 1‑800‑F...

2025-07-23 12:06:03 ET DENVER, Colo., Jul 23, 2025 ( 247marketnews.com )- Biotech stocks are making headlines again, with catalysts ranging from major international approvals and global partnerships to strategic restructurings and high-stakes market reversals. Here’s a closer loo...

2025-07-23 11:34:20 ET More on Replimune Group Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript Replimune Group: Analysts Are More Optimistic Than The Market Iovance climbs after...

New York, New York--(Newsfile Corp. - July 23, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Replimune Group, Inc. ("Replimune Group, Inc.") (NASDAQ: REPL) concerning possible violations of federal securities laws. On July 22, 2025, Replimune announced...

A look at the top 10 most actives in the United States Opendoor Technologies Inc (OPEN) fell 10.3% to $2.88 on volume of 1,046,831,357 shares Dragonfly Energy Holdings Corp (DFLI) rose 95.1% to $0.52 on volume of 683,683,260 shares Wang & Lee Group Inc. (WLGS) rose 36.1% to $0.0705 on v...

2025-07-22 15:00:51 ET Replimune Group ( REPL ) shares plummeted over 75% in trading today after the company announced the discontinuation of its RP2 and RP3 programs . The decision follows disappointing results from the Phase 2 CERPASS clinical trial, which tested RP1 in combinatio...

2025-07-22 14:08:42 ET Introduction Replimune Group, Inc.'s ( REPL ) stock is reeling following the announcement that the company received a Complete Response Letter, CRL, from the FDA for its oncolytic immunotherapy, RP1. The company had submitted a Biologics License Ap...

2025-07-22 10:54:31 ET More on Iovance Biotherapeutics, Replimune Group Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug Iovance Biotherapeutics: ASCO Update, Competitor Data And The Road Ahead Iovance: Amtagvi's Rocky Launch And Mountin...

A look at the top 10 most actives in the United States Opendoor Technologies Inc (OPEN) rose 6.9% to $3.431 on volume of 239,838,844 shares Dragonfly Energy Holdings Corp (DFLI) rose 122.3% to $0.5925 on volume of 229,549,696 shares Wang & Lee Group Inc. (WLGS) rose 27.0% to $0.0658 on ...